SCHEMBL925339

SCHEMBL925339

CC(=O)c1ccc(NC(=O)CO)cc1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.64
ALDH1A1 P00352 3/20 0.64
NPC1 O15118 7/20 0.62
SMN1; SMN2 Q16637 4/20 0.62
MAPK1 P28482 1/20 0.60
RAB9A P51151 5/20 0.56
TAAR1 Q96RJ0 1/20 0.56
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
POLB P06746 2/20 0.55
TDP1 Q9NUW8 1/20 0.55
BLM P54132 1/20 0.55
HTT P42858 2/20 0.55
NLRP1 Q9C000 1/20 0.55
ATM Q13315 1/20 0.54
GAA P10253 1/20 0.53
MCL1 Q07820 1/20 0.53
NOX1 Q9Y5S8 1/20 0.53
HPGD P15428 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2352584 0.85 MEN1 (0.56) MAPTALDH1A1NPC1SMN1; SMN2RAB9A
SCHEMBL7363709 0.84 ALDH1A1 (0.66) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL31570085 0.84 MAPT (0.64) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL7687241 0.82 MAPT (0.62) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL2556599 0.82 MAPT (0.62) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL20543330 0.82 MAPT (0.72) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL17475956 0.82 MAPT (0.62) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL8278401 0.82 MAPT (0.62) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL7932235 0.82 MAPT (0.62) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL758271 0.82 MAPT (0.62) MAPTALDH1A1NPC1SMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372866-B2 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain ROTTAPHARM S.P.A. (IT) 2013-02-12 US disclosed
EP-2268628-B1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM SPA (IT) 2012-05-16 EP disclosed
US-20110003861-A1 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM S.P.A. (IT) 2011-01-06 US disclosed
EP-2268628-A1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN Rottapharm S.p.A. (IT) 2011-01-05 EP disclosed
WO-2009109230-A1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM S.P.A. (IT) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003861-A1 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN NAT1, AADAC, OPRL1 MAPT 4791/4885ALDH1A1 401/4885NPC1 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.